RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Published April 27, 2020
Citation Information: J Clin Invest. 2020;130(6):2928-2942. https://doi.org/10.1172/JCI99417.
View: Text | PDF
Research Article Reproductive biology Article has an altmetric score of 45

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Abstract

Authors

Nadine Haase, Donald J. Foster, Mark W. Cunningham, Julia Bercher, Tuyen Nguyen, Svetlana Shulga-Morskaya, Stuart Milstein, Sarfraz Shaikh, Jeff Rollins, Michaela Golic, Florian Herse, Kristin Kräker, Ivo Bendix, Meray Serdar, Hanna Napieczynska, Arnd Heuser, Alexandra Gellhaus, Kristin Thiele, Gerd Wallukat, Dominik N. Müller, Babbette LaMarca, Ralf Dechend

×

Figure 6

siRNA against hAgt decreases the concentration of angiotensin II receptor type 1 autoantibodies (AT1-AA) in the serum of preeclamptic rats.

Options: View larger image (or click on image) Download as PowerPoint
siRNA against hAgt decreases the concentration of angiotensin II recepto...
Isolated rat neonatal cardiomyocytes were treated in vitro with IgG from luciferase-targeting siRNA–treated (n = 5) or hAgt-targeting siRNA–treated (n = 8) preeclamptic (PE) rats. Data are presented as an increase in beating rate of cardiomyocytes after treatment with IgG compared with baseline. Administration of AT1 receptor blocker (losartan) (n = 5 each) was used to show that the effect is mediated via the AT1 receptor (***P < 0.001; 1-way ANOVA with Tukey’s post hoc test; mean ± SEM).